These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20353295)
1. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Poxton IR Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ; J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839 [TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Sears P; Ichikawa Y; Ruiz N; Gorbach S Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600 [TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin versus vancomycin for Clostridium difficile infection. Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK; N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078 [TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile infection in older adults: a review and update on its management. Kee VR Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856 [TBL] [Abstract][Full Text] [Related]
7. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579 [TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S; Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770 [TBL] [Abstract][Full Text] [Related]
9. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Lancaster JW; Matthews SJ Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993 [TBL] [Abstract][Full Text] [Related]
10. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Cornely OA Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552 [TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence]. Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319 [TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections. Soriano MM; Liao S; Danziger LH Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933 [TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856 [TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Hardesty JS; Juang P Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589 [TBL] [Abstract][Full Text] [Related]
16. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166 [TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Johnson S; Gerding DN Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296 [No Abstract] [Full Text] [Related]
18. Fidaxomicin for the treatment of Clostridium difficile infections. Whitman CB; Czosnowski QA Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930 [TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Venugopal AA; Johnson S Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854 [TBL] [Abstract][Full Text] [Related]
20. [Clostridium difficile infections: update on new European recommendations]. Tissot F; Maillard MH Rev Med Suisse; 2014 Apr; 10(427):913-6, 918-9. PubMed ID: 24843988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]